Cipla gets FDA approval for generic version of Novartis’ Durezo
Cipla Limited said that it has secured final approval for its abbreviated new drug application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05% from the US Food and Drug Administration (FDA). Difluprednate Ophthalmic Emulsion 0.05% is a generic therapeutic equivalent version of Novartis Pharmaceutical’s Durezo. The drug is indicated in the US for the treatment of inflammation […]